Leadership

Dan Wildman is a Strategic Advisor to PanTher Therapeutics. A seasoned executive with more than 35 years of experience in the MedTech industry, Dan is President & Chief Executive Officer of Wildman Ventures, LLC. He also currently serves as a member of the Board of Directors or as a Strategic Adviser for several early-stage organizations.

Prior to joining PanTher Therapeutics, Dan led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc. While at Ethicon Biosurgery, he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $1.7B in revenue and continues to be one of the fastest-growing companies in J&J’s medical device portfolio.

As a strategic advisor to PanTher, Dan applies this expertise and his decades of experience to advancing the clinical development program for PTM-101 and selecting and prioritizing other Sagittari™ platform product candidates.

Dan holds a BA in Economics from St. Lawrence University.

Chelsea Reinhold is providing Clinical Operations Support to PanTher Therapeutics where she is focused on clinical trial design, strategy, and execution for current and upcoming studies. Chelsea has dedicated her career on bringing novel products to market in the oncology space.

Prior to PanTher Therapeutics, Chelsea served as Senior Clinical Project Manager at Instylla where she wore many hats including managing the first IDE study for a liquid embolic indicated for tumor embolization. Before that, she led the post-market clinical department at Augmenix, acquired by Boston Scientific for $500M+. Augmenix created a hydrogel indicated to space the rectum away from the prostate for men receiving prostate cancer radiation therapy. Chelsea was also involved in researching secondary indications for hydrogel spacers including between the pancreas and duodenum for pancreatic cancer, which resulted in a completed pilot study at Massachusetts General Hospital, MD Anderson Cancer Center, and Johns Hopkins Hospital.

Chelsea holds an MS degree in Clinical Research from Massachusetts College of Pharmacy and Health Sciences and a BS in Molecular and Cellular Biology from the University of Connecticut.

Sara Fanning is the Director of Business Operations at PanTher Therapeutics. As a business operation professional, Sara has deep experience in developing and implementing strategic projects, processes, and systems critical to company success. 

Prior to joining PanTher Therapeutics, Sara served as Director of Project Management at Evolved By Nature, where she oversaw the sustainable chemicals business unit. Before that, she served as Site Operations Manager at Bio-Rad Laboratories (formerly GnuBIO) and Manager of Administration and Operations at Brigham and Women’s Hospital. 

Sara holds a BS degree in Biological Sciences from the University of Nebraska.

Elazer Edelman, MD, PhD is the Scientific Co-Founder of PanTher Therapeutics. In addition to his role at PanTher, Elazer is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital.

Key Opinion Leader in local drug delivery and implantable devices, Elazer serves as an advisor for the FDA and several companies in the medical device industry and has been instrumental in propelling several multiple devices from conceptualization to clinical realization. He also directs MIT’s Institute for Medical Engineering and Science (IMES) and Clinical Research Center (CRC) as well as the Harvard-MIT Biomedical Engineering Center (BMEC) – all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.

Elazer holds an MD from Harvard Medical School, PhD in Medical Engineering and Medical Physics from MIT, MS degree in Electrical Engineering and Computer Sciences from MIT, and BS in Bioelectrical Engineering and in Applied Biology from MIT.

Meg Lashof-Sullivan, PhD is Associate Director of R&D at PanTher Therapeutics. As a biomedical engineer with a background in biomaterials, Meg has expertise in polymer synthesis, drug delivery, and analytical laboratory techniques. She has led the transfer of PanTher’s PTM-101 from the academic laboratory to a clinical manufacturing process. She developed the in-house testing methods used to characterize the PTM-101 prototype and has overseen the external pre-clinical studies necessary to bring PTM-101 to the clinic.

Prior to joining PanTher Therapeutics, Meg completed her postdoctoral fellowship at The Henry M. Jackson Foundation for the Advancement of Military Medicine at the Naval Medical Research Center’s NeuroTrauma department. Before that,she served as a General Engineer at the U.S. Department of Energy.

Meg holds a PhD in Biomedical Engineering from Case Western Reserve University and both a BE in Engineering and BA in Biology and Engineering from Dartmouth College.